A5088649502- Immune cells in cancer
- Neuroinflammation and Neurodegeneration Mechanisms
- Inflammation biomarkers and pathways
- Glioma Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Pancreatic and Hepatic Oncology Research
- Ferroptosis and cancer prognosis
- Renal cell carcinoma treatment
The University of Texas MD Anderson Cancer Center
2022-2024
The University of Texas Health Science Center at Houston
2023-2024
Abstract Background Glioblastomas (GBMs) are central nervous system tumors that resist standard-of-care interventions and even immune checkpoint blockade. Myeloid cells in the tumor microenvironment can contribute to GBM progression; therefore, emerging immunotherapeutic approaches include reprogramming these achieve desirable antitumor activity. Triggering receptor expressed on myeloid 2 (TREM2) is a signaling regulator has been implicated variety of cancers neurological diseases with...
Human gliomas are classified using isocitrate dehydrogenase (IDH) status as a prognosticator; however, the influence of genetic differences and treatment effects on ensuing immunity remains unclear.
The discovery of genes encoding the volume-regulated anion channel (VRAC) has enabled detailed exploration its cell type-specific roles in brain. LRRC8A (SWELL1) is essential VRAC subunit. We observed seizure-induced, subunit-specific changes microglial expression and investigated function using conditional knockout (cKO) microglia. SWELL1 cKO mice exhibited a male-specific increase kainate-induced seizure severity yet showed paradoxical neuroprotection against seizure-associated neuronal...
Abstract Glioblastomas (GBMs) are tumors of the central nervous system that remain recalcitrant to both standard care chemo-radiation and immunotherapies. Emerging approaches treat GBMs include depletion or re-education innate immune cells including microglia (MG) macrophages (MACs). Here we show myeloid cell restricted expression triggering receptor expressed on 2 (TREM2) across low- high-grade human gliomas. TREM2 did not correlate with immunosuppressive pathways, but rather showed strong...
ABSTRACT The brain tumor immune microenvironment (TIME) continuously evolves during glioma progression, but only a limited view of highly complex associated contexture across isocitrate dehydrogenase mutation (IDH) classified gliomas is known. Herein, we present an unprecedentedly comprehensive myeloid and lymphoid cell type diversity based on our single RNA sequencing spectral cytometry-based interrogation tumor-associated leukocytes from fifty-five IDH stratified primary recurrent human...
Abstract Gliomas are recalcitrant brain tumors. Differential tumor immune reactivity contributes to survival advantage of isocitrate dehydrogenase-mutant (IDHmut) over wild-type (IDHwt) gliomas. Despite this correlative pattern immunity and survival, only a limited view highly complex contexture across IDH mutation classified gliomas is known. Herein, we present an unprecedented myeloid lymphoid cell type diversity by single RNA sequencing spectral cytometry-based interrogation...
Abstract The tumor microenvironment in glioblastoma (GBM) contains numerous cell types, notably a rich immune compartment dominated by myeloid cells, such as brain-resident microglia and infiltrating macrophages. However, current immunotherapies target lymphoid components like T which are sparse the brain tumors originating there. Therefore, checkpoint drugs designed for systemic cancers have not yielded significant benefits patients with glioblastoma, efficacy of immunotherapy central...